MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

EHA 2019

Published: 20 Jun 2019

Rating:

Save

Dr Johannes Düll - University of Würzburg, Würzburg, Germany

Dr Johannes Düll speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the results from his trial of MOR208 plus lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

This meeting I presented the abstract for MorphoSys and the MOR208 antibody in combination with lenalidomide. There we could see a really great efficacy of the combination of the proposed drugs in refractory and relapsed DLBCL.

What we can see is that the objective response rates were about 60% with high CR rates. What is also interesting is that the duration of response was really great and long. We had over 60% of long-term remission patients. For the remissions that is fine and this is a hard to treat patient population. We know that from lenalidomide also the toxicity profile, so we see neutropenia, we see thrombocytopenia but nothing special, nothing unexpected. So we were really happy to have those efficacy data with long term remission in this really hard to treat patient population.

What could be the implication of this research?

That’s what next in this population and with this. These drugs with these combinations, with this data the next step will be to go to FDA for approval; maybe this could be the end of the year.